{
    "organizations": [],
    "uuid": "314ea0f3f0a78f29c7225c96709fef3a942fd251",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fusion-antibodies-says-at-least-40/brief-fusion-antibodies-says-at-least-40-pct-revenue-growth-expected-in-fy-idUSFWN1QN03K",
    "ord_in_thread": 0,
    "title": "BRIEF-Fusion Antibodies Says At Least 40 Pct Revenue Growth Expected​ in FY",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Fusion Antibodies Plc:\n* ‍FOR YEAR ENDING 31 MARCH 2018 AT LEAST 40% REVENUE GROWTH EXPECTED​\n* ‍REVENUE FOR FULL YEAR 2017/18 IS BEHIND MARKET EXPECTATIONS​\n* ‍CONTINUE TO HAVE POSITIVE OUTLOOK FOR 2018/19 IN LINE WITH EXPECTATIONS.​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T15:25:00.000+02:00",
    "crawled": "2018-03-06T22:35:56.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "fusion",
        "antibody",
        "plc",
        "year",
        "ending",
        "march",
        "least",
        "revenue",
        "growth",
        "full",
        "year",
        "behind",
        "market",
        "positive",
        "outlook",
        "line",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}